Trevena, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Trevena, Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel G-protein coupled receptor (GPCR) biased ligands for central nervous system (CNS) disorders; headquartered in Chesterbrook, Pennsylvania, and founded in 2007 based on Nobel Prize-winning research from Duke University. The company's core approved product is OLINVYK (oliceridine) injection, a mu receptor agonist for the management of moderate-to-severe acute pain in adults requiring hospital-administered IV opioids; its pipeline includes three investigational candidates in Phase 1: TRV045, an S1P receptor modulator for diabetic neuropathic pain and epilepsy in collaboration with the National Institutes of Health; TRV250, a delta receptor agonist for acute migraine; and TRV734, a mu receptor agonist for opioid use disorder. Trevena operates primarily in the United States, targeting patients with unmet needs in acute pain, neuropathic pain, migraine, epilepsy, and addiction; the company employs a functionally selective mechanism of action to preferentially activate beneficial signaling pathways while minimizing adverse effects. In July 2024, Trevena secured a $2 million non-dilutive financing tranche through an amendment to its existing ex-US royalty agreement with R-Bridge Healthcare Fund, with potential for up to an additional $8 million tied to OLINVYK U.S. partnering and commercialization milestones; the company also received a Nasdaq delisting notification in October 2024 amid ongoing financial challenges.
Trevena (NASDAQ:TRVN) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened
Critical Contrast: Ampio Pharmaceuticals (NYSE:AMPE) vs. Trevena (NASDAQ:TRVN)
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V; and bleuacacia ltd from The Nasdaq Stock Market
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Trevena Reports Third Quarter 2024 Results and Provides Business Update
Trevena Announces Receipt of Nasdaq Delisting Notification
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
What's Going On With Neurological Disease Focused Trevena On Thursday?
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN)
Trevena Reports First Quarter 2024 Results and Provides Business Update
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
Trevena Awarded OLINVYK Agreement with Premier, Inc.
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023